课题基金 / 基金详情

Targeting the eukaryotic translation initiation factor eIF4E with ribavirin in breast cancer

Targeting the eukaryotic translation initiation factor eIF4E with ribavirin in breast cancer
用利巴韦林靶向乳腺癌中的真核翻译起始因子 eIF4E
批准号：
226473
负责人：
Miller Wilson H
金额：
$30.98万
依托单位：
CIUSSS de Centre-Ouest-de-l'Ile-de-Montral-Jewish General
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2011
资助国家：
加拿大
项目状态：
已结题
起止时间：
2011-03-01 至 2014-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=226473&lang=en
关键词：
Biomarkers Breast Cancer Cell Lines Eif4e Mouse Models Ribavirin Targeted Therapy

项目摘要

项目成果

Miller Wilson H的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
An important goal in breast cancer research is to develop less toxic and more effective personalized therapies, which can be based on the presence or absence of certain proteins in the tumor. Two proteins (targets) are routinely tested in the assessment o
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploring the therapeutic potential of combined inhibition of MNK1/2 and CDK4/6 to treat melanoma.
Targeting the Mnk/eIF4E axis in the tumor microenvironment of pregnancy associated breast cancers.
Understanding the role of the MNK-eIF4E axis in the response and resistance to BRAF inhibitors.
Mechanisms of response and resistance to epigenetic therapy in hematological malignancy
海外基金